Literature DB >> 15147036

Long-term goals in the management of acute and chronic anxiety disorders.

Kevin D Kjernisted1, Pierre Bleau.   

Abstract

Many anxiety disorders are not treated to remission (symptom-free state); however, this should be the minimum goal of therapy. Antidepressant therapies have shown significant beneficial effects in the management of anxiety disorders, with some variability in results in specific disorders. In social anxiety disorder, selective serotonin reuptake inhibitors and venlafaxine extended release (XR) have demonstrated efficacy, with response rates varying between 40% and 68%. Monoamine oxidase inhibitors and cognitive-behavioural therapies are also effective. In patients with generalized anxiety disorder, benzodiazepines, paroxetine, and venlafaxine XR have demonstrated remission rates that are 15% to 25% higher than placebo. In patients with posttraumatic stress disorder, about 60% to 70% of patients experienced a response with antidepressant therapy, compared with about 40% on placebo, while remission rates in one study were 30% with venlafaxine, 24% with sertraline, and 20% with placebo. In patients with obsessive-compulsive disorder, a 25% to 35% improvement in symptom scores was reported in 20% to 65% of patients. In the management of panic disorder, paroxetine and venlafaxine XR doubled the percentage of patients who were panic-free, compared with placebo. Ongoing antidepressant therapy further improved remission rates, and many patients with anxiety disorders required extended treatment trials before experiencing benefit. In most clinical trials, some benefits were seen within 3 to 4 weeks but continued to accrue throughout the 3- to 6-month duration of the trial. In the acute phase, patients with anxiety disorders should be treated aggressively with antidepressants for extended periods and may require long-term therapy to maintain benefits. Cognitive-behavioural therapy is another mainstay in the treatment of all anxiety disorders; exposure to feared situations is necessary to move beyond phobic avoidance and functional impairment to full recovery, the ultimate goal of therapy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15147036

Source DB:  PubMed          Journal:  Can J Psychiatry        ISSN: 0706-7437            Impact factor:   4.356


  7 in total

Review 1.  Evidence Map of Yoga for Depression, Anxiety, and Posttraumatic Stress Disorder.

Authors:  Wei Duan-Porter; Remy R Coeytaux; Jennifer R McDuffie; Adam P Goode; Poonam Sharma; Hillary Mennella; Avishek Nagi; John W Williams
Journal:  J Phys Act Health       Date:  2015-07-14

Review 2.  Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders.

Authors:  Martin A Katzman; Pierre Bleau; Pierre Blier; Pratap Chokka; Kevin Kjernisted; Michael Van Ameringen; Martin M Antony; Stéphane Bouchard; Alain Brunet; Martine Flament; Sophie Grigoriadis; Sandra Mendlowitz; Kieron O'Connor; Kiran Rabheru; Peggy M A Richter; Melisa Robichaud; John R Walker
Journal:  BMC Psychiatry       Date:  2014-07-02       Impact factor: 3.630

Review 3.  Translating findings from basic fear research to clinical psychiatry in Puerto Rico.

Authors:  Gregory J Quirk; Karen G Martinez; Lelis L Nazario Rodríguez
Journal:  P R Health Sci J       Date:  2007-12       Impact factor: 0.705

4.  The Effectiveness of Art Therapy for Anxiety in Adult Women: A Randomized Controlled Trial.

Authors:  Annemarie Abbing; Erik W Baars; Leo de Sonneville; Anne S Ponstein; Hanna Swaab
Journal:  Front Psychol       Date:  2019-05-29

Review 5.  Examining the Use of Antidepressants for Adolescents with Depression/Anxiety Who Regularly Use Cannabis: A Narrative Review.

Authors:  Danielle Hen-Shoval; Aron Weller; Abraham Weizman; Gal Shoval
Journal:  Int J Environ Res Public Health       Date:  2022-01-04       Impact factor: 3.390

Review 6.  Benzodiazepines II: Waking Up on Sedatives: Providing Optimal Care When Inheriting Benzodiazepine Prescriptions in Transfer Patients.

Authors:  Jeffrey Guina; Brian Merrill
Journal:  J Clin Med       Date:  2018-01-30       Impact factor: 4.241

7.  Acceptance of Anxiety through Art Therapy: A Case Report Exploring How Anthroposophic Art Therapy Addresses Emotion Regulation and Executive Functioning.

Authors:  A C Abbing; E W Baars; O Van Haastrecht; A S Ponstein
Journal:  Case Rep Psychiatry       Date:  2019-12-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.